The NLRP1 Emerges as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Cancer Types: A Comprehensive Pan‐Cancer Analysis
Cancer Medicine · 2025
DOI: 10.1002/cam4.70836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Leila Habibipour und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Hauptthemen laut MEDLINE: Neoplasms, Biomarkers, Tumor, Adaptor Proteins, Signal Transducing, Apoptosis Regulatory Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Nod‐like receptor family pyrin domain containing 1 (NLRP1) serves as the central component of the inflammasome complex and has emerged as a potential contributor to cancer development. Despite accumulating evidence, a comprehensive assessment of NLRP1 across various cancer types has yet to be undertaken.
Methods
Several databases have evaluated NLRP1 expression across various cancer types in The Cancer Genome Atlas (TCGA). Additionally, studies have investigated the correlation between NLRP1 and various survival metrics, infiltration of cancer‐associated fibroblasts, genetic alterations, drug sensitivity, and promoter methylation. Furthermore, research has explored the potential roles of NLRP1 and its interactions with other proteins.
Results
Our analysis revealed decreased expression of NLRP1 in BLCA, BRCA, KICH, LUAD, LUSC, PRAD, and UCEC tumor tissues compared to normal tissues. We identified a significant correlation between NLRP1 expression and various cancer survival parameters, genetic mutations, and immune infiltration of cancer‐associated fibroblasts. Furthermore, we observed that NLRP1 expression is regulated by promoter DNA methylation in ESCA. Abnormal expression of NLRP1 was associated with decreased sensitivity to multiple anti‐tumor drugs and small compounds. NLRP1 was found to be involved in pathways associated with T cell receptors and chemokines.
Conclusions
Reduced NLRP1 expression contributes to cancer progression and holds potential as a crucial biomolecular marker for diagnostic, prognostic, and personalized therapeutic interventions across different malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
- Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
- Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
- Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Institute of Neuroanatomy, RWTH University Hospital Aachen, Aachen, Germany.
- Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
ORCID-Profile: Mahboubeh Sadeghi, Alireza Raghibi, Amirhossein Mohajeri Khorasani, Pegah Mousavi
Zitieren
APA
Habibipour, L., Sadeghi, M., Raghibi, A., Sanadgol, N., Mohajeri Khorasani, A., & Mousavi, P. (2025). The NLRP1 Emerges as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Cancer Types: A Comprehensive Pan‐Cancer Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.70836
Vancouver
Habibipour L, Sadeghi M, Raghibi A, Sanadgol N, Mohajeri Khorasani A, Mousavi P. The NLRP1 Emerges as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Cancer Types: A Comprehensive Pan‐Cancer Analysis. Cancer Medicine. 2025. doi:10.1002/cam4.70836
BibTeX
@article{Habibipour2025,
author = {Habibipour, Leila and Sadeghi, Mahboubeh and Raghibi, Alireza and Sanadgol, Nima and Mohajeri Khorasani, Amirhossein and Mousavi, Pegah},
title = {The NLRP1 Emerges as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Cancer Types: A Comprehensive Pan‐Cancer Analysis},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70836}
}
EUVIMED